{"content":"<li class=\"n-box-item date-title\" data-end=\"1504065599\" data-start=\"1503979200\" data-txt=\"Monday, December 23, 2019\">Tuesday, August 29, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3292535\" data-ts=\"1504046631\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDCO\" target=\"_blank\">MDCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292535-medicines-company-up-4_8-amid-fda-approval-for-vabomere\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Medicines Company up 4.8% amid FDA approval for Vabomere</a></h4><ul>   <li>The Medicines Company (<a href=\"http://seekingalpha.com/symbol/MDCO\" target=\"_blank\">MDCO</a> <font color='green'>+2.7%</font>) is <font color='green'>up 4.8%</font> after hours as its Rempex Pharmaceuticals <a href=\"https://seekingalpha.com/pr/16926741-fda-approves-new-antibacterial-drug\" target=\"_blank\">won FDA approval</a> for the use of Vabomere for adults with complicated urinary tract infections.</li>    <li>Vabomere was evaluated in a clinical trial with 545 adults with cUTI, including pyelonephritis, an infection caused by specific bacteria. The trial showed gains in comparison with another antibacterial, piperacillin/tazobactam.</li>    <li>It had gotten a priority review from the FDA as a qualified infectious disease product.</li>    <li>Vabomere contains an antibacterial (meropenem) as well as vaborbactam, which inhibits some kinds of resistance mechanisms used by bacteria.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292535\" data-linked=\"Medicines Company up 4.8% amid FDA approval for Vabomere\" data-tweet=\"$MDCO - Medicines Company up 4.8% amid FDA approval for Vabomere https://seekingalpha.com/news/3292535-medicines-company-up-4_8-amid-fda-approval-for-vabomere?source=tweet\" data-url=\"https://seekingalpha.com/news/3292535-medicines-company-up-4_8-amid-fda-approval-for-vabomere\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292534\" data-ts=\"1504046053\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVAV\" target=\"_blank\">AVAV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292534-aerovironmentplus-10-after-better-expected-quarter\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AeroVironment +10% after better than expected quarter</a></h4><ul>     <li>AeroVironment (NASDAQ:<a href='https://seekingalpha.com/symbol/AVAV' title='AeroVironment, Inc.'>AVAV</a>)&nbsp;<font color='green'>+9.8%</font>&nbsp;AH after posting a smaller than expected <a href=\"https://seekingalpha.com/news/3292487-aerovironment-eps-0_19\" target=\"_blank\">FQ1 loss</a> on above consensus revenues, with a 9% Q/Q increase in its funded backlog to $85.3M from $78M.</li>     <li>Quarterly revenues rose 21% Y/Y, resulting from sizable sales increases in its unmanned aircraft systems and efficient energy systems segments.</li>     <li>AVAV issues in-line guidance for FY 2018, seeing EPS of $0.45-$0.65 vs. $0.56 analyst consensus estimate and revenues of $280M-$300M vs. $293M consensus.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292534\" data-linked=\"AeroVironment +10% after better than expected quarter\" data-tweet=\"$AVAV - AeroVironment +10% after better than expected quarter https://seekingalpha.com/news/3292534-aerovironmentplus-10-after-better-expected-quarter?source=tweet\" data-url=\"https://seekingalpha.com/news/3292534-aerovironmentplus-10-after-better-expected-quarter\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292525\" data-ts=\"1504042635\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292525-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/AVAV' title='AeroVironment, Inc.'>AVAV</a> <font color='green'>+9.3%</font>. <a href='https://seekingalpha.com/symbol/ITCI' title='Intra-Cellular Therapies Inc.'>ITCI</a> <font color='green'>+9.1%</font>. <a href='https://seekingalpha.com/symbol/VSI' title='Vitamin Shoppe, Inc.'>VSI</a> <font color='green'>+5.0%</font>. <a href='https://seekingalpha.com/symbol/RLGY' title='Realogy Holdings'>RLGY</a> <font color='green'>+3.0%</font>. <a href='https://seekingalpha.com/symbol/BGFV' title='Big 5 Sporting Goods Corporation'>BGFV</a> <font color='green'>+1.7%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/HRB' title='H&R Block Inc.'>HRB</a> <font color='red'>-4.5%</font>. <a href='https://seekingalpha.com/symbol/SCSC' title='ScanSource, Inc.'>SCSC</a> <font color='red'>-4.1%</font>. <a href='https://seekingalpha.com/symbol/BNED' title='Barnes & Noble Education, Inc'>BNED</a> <font color='red'>-3.2%</font>. <a href='https://seekingalpha.com/symbol/QHC' title='Quorum Health Corporation'>QHC</a> <font color='red'>-3.2%</font>. <a href='https://seekingalpha.com/symbol/IGT' title='International Game Technology'>IGT</a> <font color='red'>-2.8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292525\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$AVAV $ITCI $VSI - After Hours Gainers / Losers https://seekingalpha.com/news/3292525-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3292525-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:37 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292471\" data-ts=\"1504035788\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RNN\" target=\"_blank\">RNN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292471-rexahn-pharma-up-27-on-new-u-s-nanoparticle-patent\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rexahn Pharma up 27% on new U.S. nanoparticle patent</a></h4><ul><li>Thinly traded nano cap Rexahn Pharmaceuticals (<a href='https://seekingalpha.com/symbol/RNN' title='Rexahn Pharmaceuticals Inc'>RNN</a> <font color='green'>+27.3%</font>) is up on almost double normal volume, albeit on turnover of only 577K shares, in apparent response to the <a href=\"http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&amp;Sect2=HITOFF&amp;d=PALL&amp;p=1&amp;u=/netahtml/PTO/srchnum.htm&amp;r=1&amp;f=G&amp;l=50&amp;s1=9744167.PN.&amp;OS=PN/9744167&amp;RS=PN/9744167\" target=\"_blank\">issuance of a new patent</a> (U.S. Patent No. 9,744,167) from the USPTO covering storage-stable nanoparticulate compositions and formulations of piperazine compounds used to treat and prevent proliferative diseases, including cancer.</li><li>The company's cancer-focused pipeline includes <a href=\"https://rexahn.com/cms/portfolio/rx-3117/\" target=\"_blank\">RX-3117</a>, an oral prodrug activated by a unique cancer cell enzyme called uridine cytidine kinase; <a href=\"https://rexahn.com/cms/portfolio/archexin/\" target=\"_blank\">Archexin</a>, an antisense drug that inhibits a cancer cell signaling protein called Akt-1; and <a href=\"https://rexahn.com/cms/portfolio/rx-5902/\" target=\"_blank\">Supinoxin</a>, an orally available small molecule inhibitor of a cancer protein called P-p68.</li><li><strong>Update</strong>: Shares are up&nbsp;<font color='green'>6%</font>&nbsp;premarket on Wednesday, August 30 on increased volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292471\" data-linked=\"Rexahn Pharma up 27% on new U.S. nanoparticle patent\" data-tweet=\"$RNN $REXN - Rexahn Pharma up 27% on new U.S. nanoparticle patent https://seekingalpha.com/news/3292471-rexahn-pharma-up-27-on-new-u-s-nanoparticle-patent?source=tweet\" data-url=\"https://seekingalpha.com/news/3292471-rexahn-pharma-up-27-on-new-u-s-nanoparticle-patent\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292468\" data-ts=\"1504034102\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UA\" target=\"_blank\">UA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292468-nikes-kevin-durant-throws-shade-under-armour\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nike&#39;s Kevin Durant throws shade at Under Armour</a></h4><ul>     <li>Golden State Warriors star Kevin Durant took an unexpected shot at Under Armour (NYSE:<a href='https://seekingalpha.com/symbol/UA' title='Under Armour, Inc. Class C'>UA</a>) yesterday during an interview with <a href=\"https://www.theringer.com/the-bill-simmons-podcast/2017/8/28/16214526/kevin-durant-iv-ask-kevin-anything-part-2-bill-simmons-podcast\" target=\"_blank\">The Ringer</a>.</li>     <li>\"Nobody wants to play in Under Armours. I&rsquo;m sorry. The top kids don&rsquo;t because they all play Nike,&rdquo; said KD.</li><li>Durant's teammate, Stephen Curry, is the inspiration for the UA basketball business.</li><li>Shares of Nike (<a href='https://seekingalpha.com/symbol/NKE' title='Nike Inc.'>NKE</a> <font color='red'>-2.1%</font>) and Under Armour (<a href='https://seekingalpha.com/symbol/UAA' title='Under Armour, Inc.'>UAA</a> <font color='red'>-3%</font>) are both down after a huge cut in earnings guidance from Finish Line</li><li>Previously: <a href=\"https://seekingalpha.com/news/3292218-finish-line-lowers-guidance-adopts-rights-plan\" target=\"_blank\">Finish Line lowers guidance, adopts rights plan</a> (Aug. 28)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292468\" data-linked=\"Nike&#39;s Kevin Durant throws shade at Under Armour\" data-tweet=\"$UA $UA $NKE - Nike&#39;s Kevin Durant throws shade at Under Armour https://seekingalpha.com/news/3292468-nikes-kevin-durant-throws-shade-under-armour?source=tweet\" data-url=\"https://seekingalpha.com/news/3292468-nikes-kevin-durant-throws-shade-under-armour\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>43&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292467\" data-ts=\"1504033918\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRHC\" target=\"_blank\">TRHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292467-tabula-rasa-subsidiary-inks-contract-largest-u-s-managed-care-group-for-elderly-shares-ahead\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tabula Rasa subsidiary inks contract with largest U.S. managed care group for the elderly; shares ahead 9%</a></h4><ul><li>Thinly traded micro cap Tabula Rasa Healthcare (<a href='https://seekingalpha.com/symbol/TRHC' title='Tabula Rasa HealthCare'>TRHC</a> <font color='green'>+8.8%</font>) heads north on double normal volume, albeit on turnover of only 240K shares, in response to its <a href=\"https://seekingalpha.com/pr/16925682-tabula-rasa-healthcare-s-pace-division-signs-agreement-centerlight-healthcare-pace-manage\" target=\"_blank\">announcement </a>that its wholly owned subsidiary CareKinesis has signed a contract with CenterLight Healthcare to provide medication risk management services. Contract implementation, effective September 1, will start with a single launch center and will add more sites over time. Financial terms are not disclosed.</li><li>CenterLight is the largest PACE (Program of All-Inclusive Care for the Elderly) managed care organization in the U.S. providing long-term care services throughout the greater New York City area.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292467\" data-linked=\"Tabula Rasa subsidiary inks contract with largest U.S. managed care group for the elderly; shares ahead 9%\" data-tweet=\"$TRHC - Tabula Rasa subsidiary inks contract with largest U.S. managed care group for the elderly; shares ahead 9% https://seekingalpha.com/news/3292467-tabula-rasa-subsidiary-inks-contract-largest-u-s-managed-care-group-for-elderly-shares-ahead?source=tweet\" data-url=\"https://seekingalpha.com/news/3292467-tabula-rasa-subsidiary-inks-contract-largest-u-s-managed-care-group-for-elderly-shares-ahead\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:11 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292466\" data-ts=\"1504033194\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JASO\" target=\"_blank\">JASO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292466-ja-solar-cut-to-sell-axiom-johnson-doubles-down-on-bearish-bet\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JA Solar cut to Sell at Axiom as Johnson doubles down on bearish bet</a></h4><ul>     <li>JA Solar (<a href='https://seekingalpha.com/symbol/JASO' title='JA Solar Holdings, Co., Ltd.'>JASO</a> <font color='green'>+1.7%</font>) is higher despite Axiom's <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/17/08/9990476/expert-its-time-to-short-some-of-your-solar-stocks-begin\" target=\"_blank\">downgrade to Sell</a> from Hold with a $5 price target, slashed from $7, with analyst Gordon Johnson following up <a href=\"https://seekingalpha.com/news/3291646-ja-solar-seen-bearish-light-axiom-analyst-johnson\" target=\"_blank\">last week's bearish note</a> and reiterating that the recent surge in U.S. PV prices soon could swing back in the other direction.</li>     <li>Johnson thinks Chinese solar module vendors will find themselves in a lose-lose situation whatever the outcome of Pres.&nbsp;Trump's probe into solar imports, as they will be shot out of the U.S. market or be forced to deal with deflation in U.S. PV prices if Trump opts not to act.</li><li>Johnson now has Sell ratings on JASO, Yingli Green Energy (<a href='https://seekingalpha.com/symbol/YGE' title='Yingli Green Energy Holding Company Limited'>YGE</a> <font color='red'>-0.7%</font>) and SolarEdge Technologies (<a href='https://seekingalpha.com/symbol/SEDG' title='SolarEdge Technologies'>SEDG</a> <font color='green'>+0.2%</font>), but he recommends First Solar (<a href='https://seekingalpha.com/symbol/FSLR' title='First Solar, Inc.'>FSLR</a> <font color='green'>+0.5%</font>) and Canadian Solar (<a href='https://seekingalpha.com/symbol/CSIQ' title='Canadian Solar Inc.'>CSIQ</a> <font color='green'>+1.2%</font>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3292466\" data-linked=\"JA Solar cut to Sell at Axiom as Johnson doubles down on bearish bet\" data-tweet=\"$JASO $JASO $YGE - JA Solar cut to Sell at Axiom as Johnson doubles down on bearish bet https://seekingalpha.com/news/3292466-ja-solar-cut-to-sell-axiom-johnson-doubles-down-on-bearish-bet?source=tweet\" data-url=\"https://seekingalpha.com/news/3292466-ja-solar-cut-to-sell-axiom-johnson-doubles-down-on-bearish-bet\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>34&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292463\" data-ts=\"1504032852\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DISH\" target=\"_blank\">DISH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292463-ruling-reinstate-3_3b-credits-for-dish-network-entities\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ruling could reinstate $3.3B credits for Dish Network entities</a></h4><ul>   <li>A brouhaha over $3.3B in spectrum auction credits granted to (and then taken away from) two affiliates of Dish Network (<a href=\"http://seekingalpha.com/symbol/DISH\" target=\"_blank\">DISH</a> <font color='green'>+1.6%</font>) is back in the news, as an appeals court has <a href=\"https://www.reuters.com/article/us-usa-fcc-dish-idUSKCN1B929B\" target=\"_blank\">paved a path for the credits to return</a>.</li>    <li>An appeals court ruling could nullify about $500M in fines and put the credits in play again if Northstar Wireless LLC and SNR Wireless LicenseCo LLC can prove they're independent entities from Dish.</li>    <li>The two firms are 85% owned by Dish, and of $13.3B in bids in the 2015 FCC AWS-3 spectrum auction, $3.3B were initially ruled eligible for small-business credits. The FCC eventually <a href=\"https://seekingalpha.com/news/2648325-dish-network-confirms-order-rejecting-its-auction-discounts\" target=\"_blank\">ruled the firms were ineligible</a>, and the two have made partial fine payments of about $500M to the FCC.</li>    <li>But while the appeals court said the FCC reasonably found Dish exercised \"de facto\" control, the entities must receive an opportunity to renegotiate Dish agreements to get a satisfactory amount of independence.</li>    <li>Dish and the FCC are both claiming some victory here, with Dish eager to work through concerns, and the FCC saying the court found that the agency \"reasonably determined that Dish abused a program designed to help small businesses.\"</li>    <li><a href=\"https://seekingalpha.com/news/search?query=dish%20%243.3B%20spectrum%20auction\" target=\"_blank\">Previous coverage of Dish and the AWS-3 auction</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3292463\" data-linked=\"Ruling could reinstate $3.3B credits for Dish Network entities\" data-tweet=\"$DISH - Ruling could reinstate $3.3B credits for Dish Network entities https://seekingalpha.com/news/3292463-ruling-reinstate-3_3b-credits-for-dish-network-entities?source=tweet\" data-url=\"https://seekingalpha.com/news/3292463-ruling-reinstate-3_3b-credits-for-dish-network-entities\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292462\" data-ts=\"1504032744\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292462-technology-top-gainers-losers-of-2-50-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:50 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/FENG' title='Phoenix New Media Limited'>FENG</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/VERI' title='Veritone'>VERI</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/TRHC' title='Tabula Rasa HealthCare'>TRHC</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/MARK' title='Remark Holdings, Inc.'>MARK</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/AMSWA' title='American Software, Inc.'>AMSWA</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/MOSY' title='MoSys, Inc.'>MOSY</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/CYRN' title='CYREN Ltd.'>CYRN</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/TACT' title='TransAct Technologies Incorporated'>TACT</a> <font color='red'>-5%</font>. <a href='https://seekingalpha.com/symbol/EVH' title='Evolent Health'>EVH</a> <font color='red'>-5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292462\" data-linked=\"Technology - Top Gainers / Losers as of 2:50 pm\" data-tweet=\"$FENG $VERI $TRHC - Technology - Top Gainers / Losers as of 2:50 pm https://seekingalpha.com/news/3292462-technology-top-gainers-losers-of-2-50-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3292462-technology-top-gainers-losers-of-2-50-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:52 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292457\" data-ts=\"1504031308\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FCX\" target=\"_blank\">FCX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292457-freeport-mcmoranminus-2-after-giving-up-lot-to-win-grasberg-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Freeport McMoRan -2% after giving up a lot to win Grasberg deal</a></h4><ul>     <li>Freeport McMoRan (<a href='https://seekingalpha.com/symbol/FCX' title='Freeport-McMoRan Inc.'>FCX</a> <font color='red'>-2.2%</font>) remains sharply lower, although paring earlier ~5% losses, following its agreement with the Indonesian government over the Grasberg copper mine in which it was <a href=\"https://seekingalpha.com/news/3292263-freeport-indonesia-reach-grasberg-deal\" target=\"_blank\">forced to divest 51% of its stake</a> and build a second smelter in Indonesia.</li>     <li>&ldquo;If it wasn&rsquo;t copper, this may have played out differently. But given copper&rsquo;s long-term positive outlook and the billions of dollars already invested by Freeport in Grasberg, they must realize that <a href=\"http://www.reuters.com/article/us-indonesia-freeport-idUSKCN1B90BZ\" target=\"_blank\">49% is better than nothing</a>,\" says James Wilson, mining analyst for Argonaut Stockbroking in Perth.</li>     <li>However, crucial details on the stake sale as well as additional taxes remain unresolved in the dispute; the value of the 41% stake that FCX must now sell <a href=\"https://www.wsj.com/articles/freeport-to-give-up-majority-stake-in-grasberg-mine-under-deal-with-indonesia-1503981573\" target=\"_blank\">remains to be determined</a>, and the government and its state-owned enterprises are unlikely to have the financing to buy it in one piece, analysts say.</li>     <li>&ldquo;It&rsquo;s a bit <a href=\"https://www.bloomberg.com/news/articles/2017-08-29/indonesia-says-freeport-agrees-to-new-deal-for-grasberg-mine\" target=\"_blank\">early to say</a> whether Freeport caved in or not,&rdquo; because of the uncertainties, Argonaut Securities Asia analyst Helen Lau tells Bloomberg. &ldquo;Freeport knows this mine very well and must understand it can be maintained at low costs in the long term. Ultimately this is profit driven and by agreeing this deal, Freeport can potentially benefit for 20 years.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3292457\" data-linked=\"Freeport McMoRan -2% after giving up a lot to win Grasberg deal\" data-tweet=\"$FCX - Freeport McMoRan -2% after giving up a lot to win Grasberg deal https://seekingalpha.com/news/3292457-freeport-mcmoranminus-2-after-giving-up-lot-to-win-grasberg-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3292457-freeport-mcmoranminus-2-after-giving-up-lot-to-win-grasberg-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292449\" data-ts=\"1504028043\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292449-financials-top-5-gainers-losers-of-1-30-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:30 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/FAC' title='First Acceptance Corporation'>FAC</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/LEJU' title='Leju Holdings Limited'>LEJU</a> <font color='green'>+6%</font>.<a href='https://seekingalpha.com/symbol/OPOF' title='Old Point Financial Corporation'>OPOF</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/PW' title='Power REIT'>PW</a> <font color='red'>-22%</font>. <a href='https://seekingalpha.com/symbol/RTNB' title='root9B Technologies, Inc.'>OTC:RTNB</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/HGSH' title='China HGS Real Estate, Inc.'>HGSH</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/GNBC' title='Green Bancorp'>GNBC</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292449\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:30 PM\" data-tweet=\"$FAC $LEJU $OPOF - Financials - Top 5 Gainers / Losers as of 1:30 PM https://seekingalpha.com/news/3292449-financials-top-5-gainers-losers-of-1-30-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3292449-financials-top-5-gainers-losers-of-1-30-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292438\" data-ts=\"1504024995\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292438-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/JUNO' title='Juno Therapeutics'>JUNO</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/IMGN' title='ImmunoGen, Inc.'>IMGN</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/RNN' title='Rexahn Pharmaceuticals Inc'>RNN</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/ARCX' title='Arc Logistics Partners LP'>ARCX</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/CTLT' title='Catalent'>CTLT</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/ABEO' title='Abeona Therapeutics Inc.'>ABEO</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/ARCW' title='ARC Group Worldwide, Inc.'>ARCW</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/MBRX' title='Moleculin Biotech, Inc.'>MBRX</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/APVO' title='Aptevo Therapeutics Inc.'>APVO</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/RMGN' title='RMG Networks'>RMGN</a> <font color='green'>+12%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ACOR' title='Acorda Therapeutics, Inc.'>ACOR</a> <font color='red'>-26%</font>. <a href='https://seekingalpha.com/symbol/FINL' title='The Finish Line, Inc.'>FINL</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/TNDM' title='Tandem Diabetes Care, Inc.'>TNDM</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/MOSY' title='MoSys, Inc.'>MOSY</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/JILL' title='J. Jill Group, Inc.'>JILL</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/CGG-OLD' title='CGG'>CGG-OLD</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/RTNB' title='root9B Technologies, Inc.'>OTC:RTNB</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/BBY' title='Best Buy Co.'>BBY</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/FRSH' title='Papa Murphy&#39;s Holdings, Inc.'>FRSH</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/OBSV' title='ObsEva'>OBSV</a> <font color='red'>-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292438\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$JUNO $IMGN $REXN - Midday Gainers / Losers https://seekingalpha.com/news/3292438-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3292438-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292437\" data-ts=\"1504024709\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APA\" target=\"_blank\">APA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292437-energy-shares-battered-again-harvey-continues-to-spark-uncertainty\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy shares battered again as Harvey continues to spark uncertainty</a></h4><ul>     <li>Exploration and production companies with significant exposure to Texan oil basins <a href=\"http://www.marketwatch.com/story/energy-stocks-slammed-after-hurricane-harvey-strikes-heart-of-us-oil-industry-2017-08-28\" target=\"_blank\">continue to feel the sting</a> from Harvey, extending yesterday's hefty losses:</li>     <li>The lists of decliners mostly mirrors <a href=\"https://seekingalpha.com/news/3292175-chesapeake-range-resources-lead-e-and-p-stocks-lower-harvey-hurts-demand\" target=\"_blank\">yesterday's results</a>: (<a href='https://seekingalpha.com/symbol/APA' title='Apache Corporation'>APA</a> <font color='red'>-1.9%</font>) <font color='red'>-2%</font>, (<a href='https://seekingalpha.com/symbol/XEC' title='Cimarex Energy Co.'>XEC</a> <font color='red'>-2.3%</font>) <font color='red'>-2.3%</font>, (<a href='https://seekingalpha.com/symbol/APA' title='Apache Corporation'>APA</a> <font color='red'>-1.9%</font>) <font color='red'>-1.9%</font>, (<a href='https://seekingalpha.com/symbol/RRC' title='Range Resources Corporation'>RRC</a> <font color='red'>-1.5%</font>) <font color='red'>-1.9%</font>, (<a href='https://seekingalpha.com/symbol/NFX' title='Newfield Exploration Co.'>NFX</a> <font color='red'>-1.5%</font>) <font color='red'>-1.6%</font>, (<a href='https://seekingalpha.com/symbol/SN' title='Sanchez Energy Corporation'>SN</a> <font color='red'>-2.2%</font>)&nbsp;<font color='red'>-2.1%</font>, (<a href='https://seekingalpha.com/symbol/CRZO' title='Carrizo Oil & Gas, Inc.'>CRZO</a> <font color='red'>-3.2%</font>) <font color='red'>-3%</font>, (<a href='https://seekingalpha.com/symbol/CHK' title='Chesapeake Energy Corporation'>CHK</a> <font color='red'>-1.5%</font>) <font color='red'>-1.2%</font>, (<a href='https://seekingalpha.com/symbol/EOG' title='EOG Resources, Inc.'>EOG</a> <font color='red'>-1%</font>) <font color='red'>-1.1%</font>.</li>     <li>Even some refiners, which sported strong gains yesterday, are giving back some of their gains: (<a href='https://seekingalpha.com/symbol/VLO' title='Valero Energy Corporation'>VLO</a> <font color='red'>-0.8%</font>) <font color='red'>-0.8%</font>, (<a href='https://seekingalpha.com/symbol/PSX' title='Phillips 66'>PSX</a> <font color='red'>-0.1%</font>)<font color='red'> -0.1%</font>, (<a href='https://seekingalpha.com/symbol/MPC' title='Marathon Petroleum Corp.'>MPC</a> <font color='red'>-1.9%</font>)<font color='red'> -1.8%</font>, (<a href='https://seekingalpha.com/symbol/PBF' title='PBF Energy'>PBF</a> <font color='red'>-0.4%</font>) <font color='red'>-0.4%</font>, (<a href='https://seekingalpha.com/symbol/DK' title='Delek US Holdings, Inc.'>DK</a>)&nbsp;<font color='green'>+0.1%</font>, (<a href='https://seekingalpha.com/symbol/ANDV' title='Andeavor'>ANDV</a> <font color='red'>-0.2%</font>)&nbsp;<font color='green'>+0.3%</font>, (<a href='https://seekingalpha.com/symbol/HFC' title='HollyFrontier Corp.'>HFC</a> <font color='green'>+0.7%</font>)&nbsp;<font color='green'>+0.6%</font>, (<a href='https://seekingalpha.com/symbol/CLMT' title='Calumet Specialty Products Partners, L.P.'>CLMT</a> <font color='green'>+0.8%</font>) <font color='green'>+0.7%</font>.</li>     <li>Due to the impact of flooding on labor, logistics and infrastructure, &ldquo;onshore and offshore production may not bounce back as quickly as the market is initially assuming,&rdquo; Barclays analysts say.</li>     <li>&ldquo;Moreover, the delayed impact of deferred completions in [Eagle Ford] may dent Q4 production prospects and will likely be supportive of crude and natural gas prices in the months ahead,&rdquo; the firm says.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292437\" data-linked=\"Energy shares battered again as Harvey continues to spark uncertainty\" data-tweet=\"$APA $APA $XEC - Energy shares battered again as Harvey continues to spark uncertainty https://seekingalpha.com/news/3292437-energy-shares-battered-again-harvey-continues-to-spark-uncertainty?source=tweet\" data-url=\"https://seekingalpha.com/news/3292437-energy-shares-battered-again-harvey-continues-to-spark-uncertainty\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>45&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292434\" data-ts=\"1504024309\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NKE\" target=\"_blank\">NKE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292434-nike-sized-up-finish-line-guidance-shocker\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nike sized up Finish Line guidance shocker</a></h4><ul>     <li>Shares of Nike (NYSE:<a href='https://seekingalpha.com/symbol/NKE' title='Nike Inc.'>NKE</a>) are&nbsp;<font color='red'>down 2.49%</font>&nbsp;after soft guidance from Finish Line throws a scare into investors.</li>     <li>Jefferies says the drop is warranted due to Nike's business being leveraged to Finish Line.</li>     <li>\"We can logically surmise that NKE's two largest categories (running and basketball) remain under pressure and are continuing to decelerate,\" reads the Jefferies note.</li>     <li>Morgan Stanley keeps an Outperform rating on Nike in place, but doubts are creeping in. \"The price war and weak Brand Jordan trends raise the possibility of brand equity erosion,\" observes MS.</li>     <li>Previously: <a href=\"https://seekingalpha.com/news/3292218-finish-line-lowers-guidance-adopts-rights-plan\" target=\"_blank\">Finish Line lowers guidance, adopts rights plan</a> (Aug. 28)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292434\" data-linked=\"Nike sized up Finish Line guidance shocker\" data-tweet=\"$NKE - Nike sized up Finish Line guidance shocker https://seekingalpha.com/news/3292434-nike-sized-up-finish-line-guidance-shocker?source=tweet\" data-url=\"https://seekingalpha.com/news/3292434-nike-sized-up-finish-line-guidance-shocker\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292431\" data-ts=\"1504022968\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZTO\" target=\"_blank\">ZTO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292431-zto-express-expands-fresh-produce-delivery-capacity\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ZTO Express expands fresh produce delivery capacity</a></h4><ul> <li>ZTO Express (<a href='https://seekingalpha.com/symbol/ZTO' title='ZTO Express'>ZTO</a> <font color='green'>+0.7%</font>)&nbsp;announces that it has expanded its fresh produce delivery services through the addition of high-speed rail links between Kunming, Yunnan Province, and Beijing and Shanghai.</li><li>The company notes the expansion extends ZTO's current fresh product delivery network to a total of eight high-speed rail links including Guangdong, Guangxi, Hunan, Hubei, Jiangxi and Guiyang Provinces.</li> <li>\"The addition of two high-speed rail lines between Kunming and Beijing and Shanghai in addition to the 12 airports in which we arrange air transportation will ensure the freshness of produce we deliver from Yunnan to major markets on the Chinese eastern coast,\" says ZTO chief Meisong Lai.</li>  <li>Source: <a href=\"https://seekingalpha.com/pr/16925932-zto-expands-fresh-produce-delivery-services\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3292431\" data-linked=\"ZTO Express expands fresh produce delivery capacity\" data-tweet=\"$ZTO - ZTO Express expands fresh produce delivery capacity https://seekingalpha.com/news/3292431-zto-express-expands-fresh-produce-delivery-capacity?source=tweet\" data-url=\"https://seekingalpha.com/news/3292431-zto-express-expands-fresh-produce-delivery-capacity\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292429\" data-ts=\"1504022796\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDVX\" target=\"_blank\">MDVX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292429-australia-oks-medovexs-denervex-system-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Australia OKs Medovex&#39;s DenerveX System; shares up 2%</a></h4><ul><li>The Australian Therapeutic Goods Administration <a href=\"https://seekingalpha.com/pr/16926109-medovex-corporation-receives-regulatory-approval-australias-therapeutic-goods-administration\" target=\"_blank\">approves </a>Medovex's (<a href='https://seekingalpha.com/symbol/MDVX' title='Medovex Inc.'>OTC:MDVX</a> <font color='green'>+1.7%</font>) DenerveX System for the treatment of back pain related to spinal osteoarthritis or Facet Joint Syndrome.</li><li><a href=\"http://medovex.com/denervex-providers/\" target=\"_blank\">DenerveX</a> employs a slow-rotating burr to remove facet joint (joint in the spine that enables you to bend and twist) tissue while heat ablation denudes (strips away) any residual nervous and synovial membrane overlying the joint, thereby removing the end point sensory tissue of the joint (the source of the pain).</li><li>Market launch by the company's local distributor will commence next month.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292429\" data-linked=\"Australia OKs Medovex&#39;s DenerveX System; shares up 2%\" data-tweet=\"$MDVX $HCYT - Australia OKs Medovex&#39;s DenerveX System; shares up 2% https://seekingalpha.com/news/3292429-australia-oks-medovexs-denervex-system-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3292429-australia-oks-medovexs-denervex-system-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292425\" data-ts=\"1504022404\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292425-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MOV' title='Movado Group, Inc.'>MOV</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/REED' title='Reed&#39;s, Inc.'>REED</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/SUMR' title='Summer Infant, Inc.'>SUMR</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ZX' title='China Zenix Auto International'>ZX</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/HELE' title='Helen of Troy Limited'>HELE</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/SNAK' title='Inventure Foods, Inc.'>SNAK</a> <font color='red'>-5%</font>. <a href='https://seekingalpha.com/symbol/SUP' title='Superior Industries International Inc.'>SUP</a> <font color='red'>-5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292425\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$MOV $REED $SUMR - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3292425-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3292425-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292421\" data-ts=\"1504021883\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/URGN\" target=\"_blank\">URGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292421-urogens-mitogel-fast-trackd-in-u-s-for-urothelial-carcinoma-shares-up-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UroGen&#39;s MitoGel Fast Track&#39;d in U.S. for urothelial carcinoma; shares up 3%</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/16925887-urogen-pharma-receives-fda-fast-track-designation-mitogel-treatment-upper-tract-urothelial\" target=\"_blank\">designates </a>UroGen Pharma's (<a href='https://seekingalpha.com/symbol/URGN' title='UroGen Pharma'>URGN</a> <font color='green'>+2.8%</font>) Orphan Drug-tagged MitoGel for Fast Track review for the treatment of patients with low-grade upper urinary tract urothelial carcinoma &#40;UTUC&#41; not suitable for endoscopic resection or contraindicated for the removal of the kidney and upper urinary tract (nephroureterectomy), including impaired renal function.</li><li>Phase 3-stage MitoGel, administered via an intravesical catheter, is a chemoablation agent designed to enable longer exposure to the chemo agent <a href=\"https://en.wikipedia.org/wiki/Mitomycin_C\" target=\"_blank\">Mitomycin C</a>. Its value proposition is controlling the cancer without surgically removing the involved kidney and upper tract, which is almost always problematic and has a high recurrence rate.</li><li>Fast Track status provides for more frequent interactions with the FDA review team and a rolling review of the marketing application.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292421\" data-linked=\"UroGen&#39;s MitoGel Fast Track&#39;d in U.S. for urothelial carcinoma; shares up 3%\" data-tweet=\"$URGN - UroGen&#39;s MitoGel Fast Track&#39;d in U.S. for urothelial carcinoma; shares up 3% https://seekingalpha.com/news/3292421-urogens-mitogel-fast-trackd-in-u-s-for-urothelial-carcinoma-shares-up-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3292421-urogens-mitogel-fast-trackd-in-u-s-for-urothelial-carcinoma-shares-up-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:51 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292420\" data-ts=\"1504021705\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292420-oil-slides-again-harvey-cuts-refining-capacity-dulling-demand-for-oil\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oil slides again as Harvey cuts refining capacity, dulling demand for oil</a></h4><ul>     <li><a href=\"http://www.marketwatch.com/story/oil-sees-bumpy-trade-in-harveys-aftermath-2017-08-29\" target=\"_blank\">Oil prices extend yesterday's losses</a> to trade at their lowest levels in more than a month, as refinery outages following Hurricane Harvey continue to raise concerns of weaker demand for U.S. oil; WTI <font color='red'>-1.6%</font> at $45.80/bbl, Brent <font color='red'>-0.6%</font> at $51.57.</li>     <li>&ldquo;The fact that U.S. Gulf Coast refinery capacities of ~2.5M bbl/day are out of action because of Harvey is weighing on WTI. By contrast, the oil production outages in the Gulf of Mexico and at the Eagle Ford shale play amount to less than 1M bbl/day,\" Commerzbank analysts say.</li>     <li>The storm mostly skipped the offshore platforms and instead forced refineries to shut down, which will \"increase stocks which are already far too high instead,\" Mark Yusko, CEO and  CIO at Morgan Creek Capital Management, <a href=\"https://www.cnbc.com/2017/08/29/harvey-does-something-rare-and-it-could-take-oil-on-unusual-ride.html\" target=\"_blank\">tells CNBC</a>. \"So you're going to see some negative pressure [on crude oil prices] in the short term.\"</li>     <li>Yusko is sticking with his year-end forecast of WTI in the $40-$60 range, but due to Harvey he now  expects prices will stay at the lower end of that projection longer.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>, <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UWT' title='VelocityShares 3X Long Crude ETN'>UWT</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Ultra Bloomberg Crude Oil ETF'>UCO</a>, <a href='https://seekingalpha.com/symbol/DWT' title='VelocityShares 3x Inverse Crude Oil ETN'>DWT</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/BNO' title='The United States Brent Oil ETF, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/DBO' title='PowerShares DB Oil ETF'>DBO</a>, <a href='https://seekingalpha.com/symbol/UGA' title='The United States Gasoline ETF, LP'>UGA</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>, <a href='https://seekingalpha.com/symbol/USL' title='The United States 12 Month Oil ETF, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/DNO' title='The United States Short Oil ETF, LP'>DNO</a>, <a href='https://seekingalpha.com/symbol/OLO' title='DB Crude Oil Long ETN'>OLO</a>, <a href='https://seekingalpha.com/symbol/SZO' title='DB Crude Oil Short ETN'>SZO</a>, <a href='https://seekingalpha.com/symbol/OLEM' title='iPath Pure Beta Crude Oil ETN'>OLEM</a>, <a href='https://seekingalpha.com/symbol/OILK' title='ProShares K-1 Free Crude Oil Strategy ETF'>OILK</a>, <a href='https://seekingalpha.com/symbol/WTIU' title='ProShares Daily 3x Long Crude ETN'>WTIU</a>, <a href='https://seekingalpha.com/symbol/OILX' title='Etracs S&P GSCI Crude Oil Total Return Index ETN'>OILX</a>, <a href='https://seekingalpha.com/symbol/WTID' title='ProShares Daily 3x Inverse Crude ETN'>WTID</a>, <a href='https://seekingalpha.com/symbol/USOI' title='Credit Suisse Crude Oil Shares Covered Call ETN'>USOI</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3292420\" data-linked=\"Oil slides again as Harvey cuts refining capacity, dulling demand for oil\" data-tweet=\"$USO $OIL $UWT - Oil slides again as Harvey cuts refining capacity, dulling demand for oil https://seekingalpha.com/news/3292420-oil-slides-again-harvey-cuts-refining-capacity-dulling-demand-for-oil?source=tweet\" data-url=\"https://seekingalpha.com/news/3292420-oil-slides-again-harvey-cuts-refining-capacity-dulling-demand-for-oil\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>49&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292419\" data-ts=\"1504021666\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/REED\" target=\"_blank\">REED</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292419-insider-buying-lifts-reeds\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Insider buying lifts Reed&#39;s</a></h4><ul> <li>Reed&rsquo;s (<a href='https://seekingalpha.com/symbol/REED' title='Reed&#39;s, Inc.'>REED</a> <font color='green'>+8.8%</font>)&nbsp;discloses that Chairman John Bello purchased 117,647 shares on August 24 at the market price of $1.70 per share.</li><li>Chairman Bello purchased an additional 29,400 shares on August 25 at $1.70 per share.</li><li>Source: <a href=\"https://seekingalpha.com/pr/16925881-reed-s-inc-chairman-john-bello-purchases-147047-shares-common-stock\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3292419\" data-linked=\"Insider buying lifts Reed&#39;s\" data-tweet=\"$REED - Insider buying lifts Reed&#39;s https://seekingalpha.com/news/3292419-insider-buying-lifts-reeds?source=tweet\" data-url=\"https://seekingalpha.com/news/3292419-insider-buying-lifts-reeds\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292418\" data-ts=\"1504021512\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COST\" target=\"_blank\">COST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292418-cowen-sees-costco-running-to-new-highs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cowen sees Costco running to new highs</a></h4><ul> <li>Cowen <a href=\"https://twitter.com/CowenResearch/status/902529459676487682\" target=\"_blank\">backs</a> an Outperform rating on Costco (<a href='https://seekingalpha.com/symbol/COST' title='Costco Wholesale Corporation'>COST</a> <font color='green'>+0.3%</font>) after hearing from management at the retailer's headquarters.</li> <li>Analyst Oliver Chen thinks more brands will look to partner with Costco amid the industry store closing cycle and calls the near term strategies compelling.</li> <li>\"We view COST's vertical integration, including recently breaking ground on a new poultry facility and strong relationships with farmers as competitive advantages that are difficult for competitors to replicate,\" he adds.</li><li>Cowen's price target on Costco is lifted to $182 to rep 19% upside potential.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292418\" data-linked=\"Cowen sees Costco running to new highs\" data-tweet=\"$COST - Cowen sees Costco running to new highs https://seekingalpha.com/news/3292418-cowen-sees-costco-running-to-new-highs?source=tweet\" data-url=\"https://seekingalpha.com/news/3292418-cowen-sees-costco-running-to-new-highs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292414\" data-ts=\"1504020616\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRQR\" target=\"_blank\">PRQR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292414-dosing-completed-in-proqrs-early-stage-study-of-cf-candidate-qrminus-010-top-line-results-to\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dosing completed in ProQR&#39;s early-stage study of CF candidate QR-010, top-line results to be released in a month; shares up 9%</a></h4><ul><li>ProQR Therapeutics N.V. (<a href='https://seekingalpha.com/symbol/PRQR' title='ProQR Therapeutics'>PRQR</a> <font color='green'>+8.7%</font>) <a href=\"https://seekingalpha.com/pr/16925653-proqr-completes-dosing-cystic-fibrosis-patients-qrminus-010-phase-1b-trial\" target=\"_blank\">announces </a>the completion of patient dosing in its Phase 1b clinical trial evaluating lead candidate QR-010 in cystic fibrosis &#40;CF&#41;&nbsp;patients. It plans to release top-line data on Monday, September 25 after the close.</li><li>CF is caused by mutations in a protein called CFTR.&nbsp;<a href=\"http://www.proqr.com/cf/\" target=\"_blank\">QR-010</a>&nbsp;is an inhaled therapy designed to repair the genetic defect in RNA which will result in the synthesis of a normal healthy CFTR protein.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3217527-proqrs-lead-product-candidate-successful-early-stage-cf-study-shares-ahead-33-percent\" target=\"_blank\">ProQR's lead product candidate successful in early-stage CF study; shares ahead 33% premarket</a> (Oct. 27, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3292414\" data-linked=\"Dosing completed in ProQR&#39;s early-stage study of CF candidate QR-010, top-line results to be released in a month; shares up 9%\" data-tweet=\"$PRQR - Dosing completed in ProQR&#39;s early-stage study of CF candidate QR-010, top-line results to be released in a month; shares up 9% https://seekingalpha.com/news/3292414-dosing-completed-in-proqrs-early-stage-study-of-cf-candidate-qrminus-010-top-line-results-to?source=tweet\" data-url=\"https://seekingalpha.com/news/3292414-dosing-completed-in-proqrs-early-stage-study-of-cf-candidate-qrminus-010-top-line-results-to\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292415\" data-ts=\"1504020445\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COL\" target=\"_blank\">COL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292415-wsj-united-technologies-near-20b-plus-deal-to-buy-rockwell-collins\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WSJ: United Technologies near $20B-plus deal to buy Rockwell Collins</a></h4><ul>     <li>Rockwell Collins (<a href='https://seekingalpha.com/symbol/COL' title='Rockwell Collins, Inc.'>COL</a> <font color='green'>+1.6%</font>) pops following a <em>WSJ</em> report that United Technologies (<a href='https://seekingalpha.com/symbol/UTX' title='United Technologies Corporation'>UTX</a> <font color='green'>+1.2%</font>) is <a href=\"https://www.wsj.com/articles/united-technologies-nears-deal-to-buy-rockwell-collins-for-more-than-20-billion-1504019858\" target=\"_blank\">near an agreement to buy the company</a> for more than $20B.</li>     <li>The companies are discussing a price of $140/share or less and could come to an agreement as soon as this weekend, according to the report.</li>     <li>Reports have circulated for weeks about a potential tie-up that would create one of the world&rsquo;s biggest aircraft-equipment makers, and <a href=\"https://seekingalpha.com/news/3291587-rockwell-postpones-upcoming-road-show\" target=\"_blank\">last week</a> COL said it pulled out of a road show due to a scheduling conflict.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292415\" data-linked=\"WSJ: United Technologies near $20B-plus deal to buy Rockwell Collins\" data-tweet=\"$COL $COL $UTX - WSJ: United Technologies near $20B-plus deal to buy Rockwell Collins https://seekingalpha.com/news/3292415-wsj-united-technologies-near-20b-plus-deal-to-buy-rockwell-collins?source=tweet\" data-url=\"https://seekingalpha.com/news/3292415-wsj-united-technologies-near-20b-plus-deal-to-buy-rockwell-collins\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292407\" data-ts=\"1504019273\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABEO\" target=\"_blank\">ABEO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292407-abeonas-ebminus-101-breakthrough-therapy-in-u-s-for-rare-skin-blistering-disorder-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Abeona&#39;s EB-101 a Breakthrough Therapy in U.S. for rare skin-blistering disorder; shares ahead 8%</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/16926093-abeona-therapeutics-receives-fda-breakthrough-therapy-designation-ebminus-101-autologous-cell\" target=\"_blank\">designates </a>Abeona Therapeutics' (<a href='https://seekingalpha.com/symbol/ABEO' title='Abeona Therapeutics Inc.'>ABEO</a> <font color='green'>+7.9%</font>) lead cell therapy candidate, Orphan Drug-tagged EB-101, a Breakthrough Therapy for the treatment of <a href=\"http://www.mayoclinic.org/diseases-conditions/epidermolysis-bullosa/basics/definition/con-20032497\" target=\"_blank\">epidermolysis bullosa</a>, a rare inherited disorder characterized by large painful blisters on the skin.</li><li>Breakthrough Therapy status provides for more intensive guidance from the FDA on development, the involvement of more senior agency personnel and a rolling review of the marketing application.</li><li>EB-101 is currently in <a href=\"https://clinicaltrials.gov/ct2/show/NCT02579369?term=eb-101&amp;rank=2\" target=\"_blank\">Phase 2</a> development.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3269913-abeonas-gene-therapy-ebminus-101-orphan-drug-rare-inherited-skin-blistering-disorder\" target=\"_blank\">Abeona's gene therapy EB-101 an Orphan Drug for rare inherited skin-blistering disorder</a> (May 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3292407\" data-linked=\"Abeona&#39;s EB-101 a Breakthrough Therapy in U.S. for rare skin-blistering disorder; shares ahead 8%\" data-tweet=\"$ABEO - Abeona&#39;s EB-101 a Breakthrough Therapy in U.S. for rare skin-blistering disorder; shares ahead 8% https://seekingalpha.com/news/3292407-abeonas-ebminus-101-breakthrough-therapy-in-u-s-for-rare-skin-blistering-disorder-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3292407-abeonas-ebminus-101-breakthrough-therapy-in-u-s-for-rare-skin-blistering-disorder-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:07 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292373\" data-ts=\"1504018807\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292373-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/RNN' title='Rexahn Pharmaceuticals Inc'>RNN</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/JUNO' title='Juno Therapeutics'>JUNO</a> <font color='green'>+16%</font>.<a href='https://seekingalpha.com/symbol/IMGN' title='ImmunoGen, Inc.'>IMGN</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/CTLT' title='Catalent'>CTLT</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/PRQR' title='ProQR Therapeutics'>PRQR</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ACOR' title='Acorda Therapeutics, Inc.'>ACOR</a> <font color='red'>-27%</font>. <a href='https://seekingalpha.com/symbol/TNDM' title='Tandem Diabetes Care, Inc.'>TNDM</a> <font color='red'>-12%</font>. VRX <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/MESO' title='Mesoblast'>MESO</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/AKAO' title='Achaogen'>AKAO</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292373\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$REXN $JUNO $IMGN - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3292373-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3292373-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292397\" data-ts=\"1504018162\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHC\" target=\"_blank\">BHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292397-valeant-continues-slide-down-8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Valeant continues slide, down 8%</a></h4><ul><li>Valeant Pharmaceuticals (VRX <font color='red'>-8%</font>) continues to test the resolve of value investors and bargain hunters. Shares are down on modestly higher volume on the heels of a bearish $7 price target by Mizuho Securities which maintains its Underperform rating.</li><li>Analyst Irina Koffler cites a range of weaknesses in the company's business and expects it to miss its 2017 revenue and EBITDA guidance, adding that its Dental unit is no longer strategically attractive due to reimbursement headwinds.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3292397\" data-linked=\"Valeant continues slide, down 8%\" data-tweet=\"$BHC - Valeant continues slide, down 8% https://seekingalpha.com/news/3292397-valeant-continues-slide-down-8?source=tweet\" data-url=\"https://seekingalpha.com/news/3292397-valeant-continues-slide-down-8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>91&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292388\" data-ts=\"1504016600\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSLA\" target=\"_blank\">TSLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292388-tesla-lower-uber-ceo-news-analyzed\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tesla lower as Uber CEO news analyzed</a></h4><ul> <li>Tesla (NASDAQ:<a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a>) is&nbsp;<font color='red'>down 1.86%</font>&nbsp;in a move that is being attributed in part to Uber's (<a href='https://seekingalpha.com/symbol/UBER' title='Uber'>UBER</a>) expected hiring of Expedia CEO Dara Khosrowshahi to lead the company.</li> <li>KeyBanc calls the development an important shift by Uber to value the marketplace over cars, which in turns diminishes the odds for an extensive Tesla-Uber partnership.</li> <li>There's also a note out from Baird on negative survey responses from Tesla customers on service and quality, although the overall read-through on Tesla owner loyalty is positive.</li> <li>Source: Bloomberg</li><li>Previously: <a href=\"https://seekingalpha.com/news/3292166-expedia-board-member-says-ceo-intends-leave-uber\" target=\"_blank\">Expedia board member says CEO intends to leave for Uber</a> (Aug. 28)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292388\" data-linked=\"Tesla lower as Uber CEO news analyzed\" data-tweet=\"$TSLA $TSLA $UBER - Tesla lower as Uber CEO news analyzed https://seekingalpha.com/news/3292388-tesla-lower-uber-ceo-news-analyzed?source=tweet\" data-url=\"https://seekingalpha.com/news/3292388-tesla-lower-uber-ceo-news-analyzed\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>75&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292387\" data-ts=\"1504016538\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CY\" target=\"_blank\">CY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292387-craig-hallum-analyst-questions-cypress-semis-involvement-in-next-iphones\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Craig-Hallum analyst questions Cypress Semi&#39;s involvement in next iPhones</a></h4><ul><li>        Craig-Hallum reiterates a Buy rating and $20 price target on Cypress Semiconductor (NASDAQ:<a href='https://seekingalpha.com/symbol/CY' title='Cypress Semiconductor Corporation'>CY</a>).</li><li>               Analyst Anthony Stoss says checks make it doubtful that the new iPhones will include a super-fast USB-C charging cord and will instead feature a cheaper model.&nbsp;</li><li>               Stoss says not appearing in the box can limit Cypress&rsquo; upside but he hadn&rsquo;t factored in much Apple input in his previous estimates.&nbsp;</li><li>               Source: <a href=\"https://thefly.com/permalinks/entry.php/id2602271/CY;AAPL-CraigHallum-still-buyer-of-Cypress-as-Apple-plans-not-to-include-fast-charging\" target=\"_blank\">The Fly</a>&nbsp;</li><li>               Cypress Semiconductor shares are&nbsp;<font color='red'>down 2.52%</font>.&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3292387\" data-linked=\"Craig-Hallum analyst questions Cypress Semi&#39;s involvement in next iPhones\" data-tweet=\"$CY - Craig-Hallum analyst questions Cypress Semi&#39;s involvement in next iPhones https://seekingalpha.com/news/3292387-craig-hallum-analyst-questions-cypress-semis-involvement-in-next-iphones?source=tweet\" data-url=\"https://seekingalpha.com/news/3292387-craig-hallum-analyst-questions-cypress-semis-involvement-in-next-iphones\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292381\" data-ts=\"1504015526\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JUNO\" target=\"_blank\">JUNO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292381-buying-continues-in-juno-therapeutics-shares-up-16\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Buying continues in Juno Therapeutics, shares up 16%</a></h4><ul><li>Investors continue to show Juno Therapeutics (<a href='https://seekingalpha.com/symbol/JUNO' title='Juno Therapeutics'>JUNO</a> <font color='green'>+15.9%</font>) some love after Gilead's $11.9B takeout of Kite Pharma. Raymond James and Wedbush both upgraded the stock to Outperform. Shares are up&nbsp;<font color='green'>33%</font>&nbsp;this week.</li><li>The company's lead CAR-T candidate is <a href=\"https://www.junotherapeutics.com/our-pipeline/\" target=\"_blank\">JCAR017</a>, in <a href=\"https://clinicaltrials.gov/ct2/show/NCT02631044?term=jcar017&amp;rank=1\" target=\"_blank\">Phase 1</a> development for the treatment of B-cell non-Hodgkin lymphoma. According to ClinicalTrials.gov, the estimated primary completion date is October 2018.</li><li>In March, the company terminated development of former lead candidate JCAR015 due to safety concerns, specifically the risk of cerebral edema.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3292178-analysts-weigh-ripple-effect-gilead-kite-marriage\" target=\"_blank\">Analysts weigh in on ripple effect from Gilead/Kite marriage</a> (Aug. 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3292381\" data-linked=\"Buying continues in Juno Therapeutics, shares up 16%\" data-tweet=\"$JUNO - Buying continues in Juno Therapeutics, shares up 16% https://seekingalpha.com/news/3292381-buying-continues-in-juno-therapeutics-shares-up-16?source=tweet\" data-url=\"https://seekingalpha.com/news/3292381-buying-continues-in-juno-therapeutics-shares-up-16\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292371\" data-ts=\"1504013881\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292371-dollar-sinks-to-two-year-low-goldman-says-to-get-long\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dollar sinks to more than a two-year low; Goldman says to get long</a></h4><ul><li>An overnight North Korean rocket launch is hitting stocks globally, but it's not enough to arrest the strong downtrend in King Dollar, which is&nbsp;<font color='red'>off another 0.4%&nbsp;</font>to its lowest level since early 2015.</li><li>The dollar's slide began at the start of this year. Pick your reason, but one decent one - the Fed then was the only hawkish central bank around. Two rate hikes later, investors are questioning whether the Fed might move to the sidelines for at least a bit while other central banks take up the hawkish mandate.</li><li>Goldman for years has among the most strident U.S. economy bulls, and it's not giving that up. Mike Swell from the bank's asset management operation fully expects the Fed to continue with a string of rate hikes, and - while acknowledging that long dollar has been quite the pain trade - says now's a \"very, very attractive\" time to buy greenbacks.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/UUP' title='PowerShares DB USD Bull ETF'>UUP</a>, <a href='https://seekingalpha.com/symbol/UDN' title='PowerShares DB USD Bear ETF'>UDN</a>, <a href='https://seekingalpha.com/symbol/USDU' title='WisdomTree Bloomberg U.S. Dollar Bullish ETF'>USDU</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3292371\" data-linked=\"Dollar sinks to more than a two-year low; Goldman says to get long\" data-tweet=\"$UUP $UDN $USDU - Dollar sinks to more than a two-year low; Goldman says to get long https://seekingalpha.com/news/3292371-dollar-sinks-to-two-year-low-goldman-says-to-get-long?source=tweet\" data-url=\"https://seekingalpha.com/news/3292371-dollar-sinks-to-two-year-low-goldman-says-to-get-long\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292369\" data-ts=\"1504013487\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARCX\" target=\"_blank\">ARCX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292369-arc-logistics-partners-to-be-bought-zenith-energy-for-16_50-unit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arc Logistics Partners to be bought by Zenith Energy for $16.50/unit</a></h4><ul>     <li>Arc Logistics Partners (<a href='https://seekingalpha.com/symbol/ARCX' title='Arc Logistics Partners LP'>ARCX</a> <font color='green'>+10.3%</font>) <a href=\"https://seekingalpha.com/pr/16926028-arc-logistics-partners-lp-enters-definitive-agreement-acquired-zenith\" target=\"_blank\">agrees to be acquired</a> by Zenith Energy for $16.50/unit, a 15% premium to yesterday's closing price.</li>     <li>The deal is subject to the closing of purchases by Zenith from EFS Midstream Holdings of certain of the interests in Arc Terminals Joliet Holdings, which indirectly owns a crude oil unloading facility and a crude oil pipeline in Joliet, Ill., and a 5.5% interest in Gulf LNG Holdings, which owns a liquefied natural gas regasification  and storage facility in Pascagoula, Miss., from Lightfoot Capital Partners.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292369\" data-linked=\"Arc Logistics Partners to be bought by Zenith Energy for $16.50/unit\" data-tweet=\"$ARCX - Arc Logistics Partners to be bought by Zenith Energy for $16.50/unit https://seekingalpha.com/news/3292369-arc-logistics-partners-to-be-bought-zenith-energy-for-16_50-unit?source=tweet\" data-url=\"https://seekingalpha.com/news/3292369-arc-logistics-partners-to-be-bought-zenith-energy-for-16_50-unit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292360\" data-ts=\"1504012619\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MBRX\" target=\"_blank\">MBRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292360-moleculin-files-ind-for-leukemia-med-annamycin-shares-ahead-17-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Moleculin files IND for leukemia med Annamycin; shares ahead 17% premarket</a></h4><ul><li>Nano cap Moleculin Biotech (NASDAQ:<a href='https://seekingalpha.com/symbol/MBRX' title='Moleculin Biotech, Inc.'>MBRX</a>) is up&nbsp;<font color='green'>17%</font>&nbsp;premarket on average volume in response to its <a href=\"https://seekingalpha.com/pr/16925681-moleculin-announces-filing-fda-ind-leukemia-drug-annamycin\" target=\"_blank\">announcement </a>that it has filed an Investigational New Drug &#40;IND&#41; application with the FDA seeking approval to start clinical trials to investigate Annamycin for the treatment of relapsed/refractory acute myeloid leukemia &#40;AML&#41;. If the FDA signs off as expected, clinical studies could begin as early as Q4.</li><li>Annamycin is a member of the anthracycline class of chemotherapeutic agents (includes doxorubicin). Its value proposition is less cardiotoxicity and greater ability to overcome multidrug resistance mechanisms.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3279189-moleculin-licenses-leukemia-candidate-md-anderson-shares-ahead-28-percent-premarket\" target=\"_blank\">Moleculin in-licenses leukemia candidate from MD Anderson; shares ahead 28% premarket</a> (July 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3292360\" data-linked=\"Moleculin files IND for leukemia med Annamycin; shares ahead 17% premarket\" data-tweet=\"$MBRX - Moleculin files IND for leukemia med Annamycin; shares ahead 17% premarket https://seekingalpha.com/news/3292360-moleculin-files-ind-for-leukemia-med-annamycin-shares-ahead-17-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3292360-moleculin-files-ind-for-leukemia-med-annamycin-shares-ahead-17-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292359\" data-ts=\"1504012557\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292359-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/MBRX' title='Moleculin Biotech, Inc.'>MBRX</a> <font color='green'>+16%</font>&nbsp;as they <a href=\"https://seekingalpha.com/news/3290921\" target=\"_blank\">meet</a> with EMA on trial design for AML candidate Annamycin.</li>     <li><a href='https://seekingalpha.com/symbol/IMGN' title='ImmunoGen, Inc.'>IMGN</a> <font color='green'>+9%</font>&nbsp;on&nbsp;&nbsp;ADC development <a href=\"https://seekingalpha.com/news/3292314-immunogen-inks-adc-development-deal-jazz-pharma-valued-least-175m-shares-ahead-11-percent\" target=\"_blank\">deal</a> with Jazz Pharma.</li>     <li><a href='https://seekingalpha.com/symbol/HAIN' title='The Hain Celestial Group, Inc.'>HAIN</a> <font color='green'>+8%</font>&nbsp;on Q4 <a href=\"https://seekingalpha.com/news/3292305\" target=\"_blank\">result</a>.</li>     <li><a href='https://seekingalpha.com/symbol/ABCO' title='The Advisory Board Company'>ABCO</a> <font color='green'>+6%</font>&nbsp;on asset <a href=\"https://seekingalpha.com/news/3292342\" target=\"_blank\">sale</a>.</li>     <li><a href='https://seekingalpha.com/symbol/HMY' title='Harmony Gold Mining Company Limited'>HMY</a> <font color='green'>+6%</font>&nbsp;on geopolitical <a href=\"https://seekingalpha.com/news/3292315\" target=\"_blank\">risk</a>.</li>     <li><a href='https://seekingalpha.com/symbol/EGO' title='Eldorado Gold Corporation'>EGO</a> <font color='green'>+5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292359\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$MBRX $IMGN $HAIN - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3292359-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3292359-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292356\" data-ts=\"1504012410\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292356-odds-dwindle-for-2017-rate-hikes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Odds dwindle for any more 2017 rate hikes</a></h4><ul><li>The hawks and even some middle-of-the-roaders on the FOMC no doubt want to raise rates again at the mid-September meeting, but those who buy, sell, and hedge the level of short-term interest rates<a href=\"http://www.cmegroup.com/trading/interest-rates/stir/30-day-federal-fund.html\" target=\"_blank\"> are now pricing in less</a> than a 25% chance of another rate hike at any point for the rest of the year.</li><li>Helping today's drop in rate hike expectations is North Korea's missile launch. Bigger picture, the regulatory reform and tax cuts promised by the current administration are bogged down in the D.C. mud.</li><li>Checking the long end of the curve, the 10-year Treasury yield <a href=\"https://seekingalpha.com/news/3292321-10-year-treasury-yield-slumps-new-2017-low\" target=\"_blank\">has dropped</a> four basis points to a new 2017-low of 2.11%.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/IEF' title='iShares 7-10 Year Treasury Bond ETF'>IEF</a>, <a href='https://seekingalpha.com/symbol/PST' title='ProShares UltraShort 7-10 Year Treasury ETF'>PST</a>, <a href='https://seekingalpha.com/symbol/IEI' title='iShares 3-7 Year Treasury Bond ETF'>IEI</a>, <a href='https://seekingalpha.com/symbol/UST' title='ProShares Ultra 7-10 Year Treasury ETF'>UST</a>, <a href='https://seekingalpha.com/symbol/DTYS' title='iPath U.S. Treasury 10-Year Bear ETN'>DTYS</a>, <a href='https://seekingalpha.com/symbol/VGIT' title='Vanguard Intermediate-Term Government Bond Index ETF'>VGIT</a>, <a href='https://seekingalpha.com/symbol/TYO' title='Direxion Daily 10-Year Treasury Bear 3x Shares ETF'>TYO</a>, <a href='https://seekingalpha.com/symbol/GSY' title='Guggenheim Enhanced Short Duration ETF'>GSY</a>, <a href='https://seekingalpha.com/symbol/SCHR' title='Schwab Intermediate-Term U.S. Treasury ETF'>SCHR</a>, <a href='https://seekingalpha.com/symbol/TBX' title='ProShares Short 7-10 Year Treasury ETF'>TBX</a>, <a href='https://seekingalpha.com/symbol/TYD' title='Direxion Daily 10-Year Treasury Bull 3x Shares ETF'>TYD</a>, <a href='https://seekingalpha.com/symbol/ITE' title='SPDR Barclays Intermediate Term Treasury ETF'>ITE</a>, <a href='https://seekingalpha.com/symbol/DTYL' title='iPath U.S. Treasury 10-Year Bull ETN'>DTYL</a>, <a href='https://seekingalpha.com/symbol/DFVL' title='iPath U.S. Treasury 5-Year Bull ETN'>DFVL</a>, <a href='https://seekingalpha.com/symbol/DFVS' title='iPath U.S. Treasury 5-Year Bear ETN'>DFVS</a>, <a href='https://seekingalpha.com/symbol/TBZ' title='ProShares UltraShort 3-7 Year Treasury ETF'>TBZ</a>, <a href='https://seekingalpha.com/symbol/TYNS' title='Direxion Daily 7-10 Year Treasury Bear 1x Shares ETF'>TYNS</a>, <a href='https://seekingalpha.com/symbol/HYDD' title='Direxion Daily High Yield Bear 2x Shares ETF'>HYDD</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3292356\" data-linked=\"Odds dwindle for any more 2017 rate hikes\" data-tweet=\"$IEF $PST $IEI - Odds dwindle for any more 2017 rate hikes https://seekingalpha.com/news/3292356-odds-dwindle-for-2017-rate-hikes?source=tweet\" data-url=\"https://seekingalpha.com/news/3292356-odds-dwindle-for-2017-rate-hikes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292355\" data-ts=\"1504012285\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292355-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/FINL' title='The Finish Line, Inc.'>FINL</a>&nbsp;<font color='red'>-32%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3292218-finish-line-lowers-guidance-adopts-rights-plan\" target=\"_blank\">lowering</a> guidance.</li><li><a href='https://seekingalpha.com/symbol/ACOR' title='Acorda Therapeutics, Inc.'>ACOR</a>&nbsp;<font color='red'>-32%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3292304-fda-rejects-acordas-marketing-application-parkinsons-candidate-inbrija-shares-24-percent\" target=\"_blank\">receiving</a> refusal to file letter from FDA for INBRIJA.</li><li><a href='https://seekingalpha.com/symbol/JILL' title='J. Jill Group, Inc.'>JILL</a>&nbsp;<font color='red'>-11%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3292291-j-jill-eps-line-beats-revenue\" target=\"_blank\">Q2 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/AVEO' title='AVEO Pharmaceuticals, Inc.'>AVEO</a> <font color='red'>-7%</font>.</li><li><a href='https://seekingalpha.com/symbol/TNDM' title='Tandem Diabetes Care, Inc.'>TNDM</a> <font color='red'>-6%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3292355\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$FINL $ACOR $JILL - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3292355-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3292355-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292342\" data-ts=\"1504011093\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABCO\" target=\"_blank\">ABCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292342-advisory-board-rallies-after-asset-sales\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">The Advisory Board rallies after asset sales</a></h4><ul> <li>Shares of The Advisory Board Company (NASDAQ:<a href='https://seekingalpha.com/symbol/ABCO' title='The Advisory Board Company'>ABCO</a>)&nbsp;<font color='green'>jump 6.4%</font>&nbsp;in premarket trading after the company struck a deal earlier this morning to sell its health care and education businesses for a cool $2.58B.</li> <li>Both deals are expected to close either this year or early in 2018.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3292311-advisory-board-company-sells-health-care-education-businesses\" target=\"_blank\">The Advisory Board Company sells health care and education businesses</a> (Aug. 29)</li> <li>ABCO <font color='green'>+6.72%</font> premarket to $53.20.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292342\" data-linked=\"The Advisory Board rallies after asset sales\" data-tweet=\"$ABCO - The Advisory Board rallies after asset sales https://seekingalpha.com/news/3292342-advisory-board-rallies-after-asset-sales?source=tweet\" data-url=\"https://seekingalpha.com/news/3292342-advisory-board-rallies-after-asset-sales\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:51 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292335\" data-ts=\"1504010286\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DRIO\" target=\"_blank\">DRIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292335-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>DarioHealth (NASDAQ:<a href='https://seekingalpha.com/symbol/DRIO' title='DarioHealth Corp.'>DRIO</a>) initiated with Buy rating and $3.50 (75% upside) price target by Aegis Capital.</li><li>AveXis (NASDAQ:<a href='https://seekingalpha.com/symbol/AVXS' title='AveXis'>AVXS</a>) initiated with Reduce rating and $52 (46% downside risk) price target by Instinet. Shares are down&nbsp;<font color='red'>3%</font>&nbsp;premarket on light volume.</li><li>Esperion Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ESPR' title='Esperion Therapeutics'>ESPR</a>) initiated with Outperform rating and $72 (47% upside) price target by Northland Capital. Shares are down&nbsp;<font color='red'>3%</font>&nbsp;premarket on light volume.</li><li>Juno Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/JUNO' title='Juno Therapeutics'>JUNO</a>) upgraded to Outperform by Raymond James. Upgraded to Outperform by Wedbush. Shares are up&nbsp;<font color='green'>1%</font>&nbsp;premarket on light volume.</li><li>Loxo Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/LOXO' title='Loxo Oncology'>LOXO</a>) downgraded to Market Perform by JMP Securities.</li><li>Valeant Pharmaceuticals (VRX) price target lowered to $7 (51% downside risk) by Mizuho Securities. Shares are down&nbsp;<font color='red'>1%</font>&nbsp;premarket on light volume.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3292335\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$DRIO $DRIO $AVXS - Premarket analyst action - healthcare https://seekingalpha.com/news/3292335-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3292335-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292321\" data-ts=\"1504009192\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292321-10-year-treasury-yield-slumps-to-new-2017-low\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">10-year Treasury yield slumps to new 2017 low</a></h4><ul><li>To review, the 10-year yield stood at about 1.85% just ahead of November's election. Following that surprise result, it quickly jumped to about 2.20%, and rose to as high as 2.55% in January as investors priced in rate hikes, tax cuts, regulatory reform, and a surging economy.</li><li>Two rates hikes and several months of the new administration later, the yield has fallen all the way back to 2.11%. It's off four basis points today, with jitters over a North Korean missile launch the apparent cause.</li><li>As for monetary policy, Janet Yellen's Friday speech at Jackson Hole didn't touch on it, leaving investors continuing to speculate on the odds of a September move by the FOMC.</li><li><a href='https://seekingalpha.com/symbol/TLT' title='iShares 20+ Year Treasury Bond ETF'>TLT</a>&nbsp;<font color='green'>+0.75%</font>, <a href='https://seekingalpha.com/symbol/TBT' title='ProShares UltraShort 20+ Year Treasury ETF'>TBT</a>&nbsp;<font color='red'>-1.5%</font>&nbsp;premarket</li><li>ETFs: <a href='https://seekingalpha.com/symbol/TLT' title='iShares 20+ Year Treasury Bond ETF'>TLT</a>, <a href='https://seekingalpha.com/symbol/TBT' title='ProShares UltraShort 20+ Year Treasury ETF'>TBT</a>, <a href='https://seekingalpha.com/symbol/TMV' title='Direxion Daily 20+ Year Treasury Bear 3x Shares ETF'>TMV</a>, <a href='https://seekingalpha.com/symbol/TBF' title='ProShares Short 20+ Year Treasury ETF'>TBF</a>, <a href='https://seekingalpha.com/symbol/EDV' title='Vanguard Extended Duration Treasury ETF'>EDV</a>, <a href='https://seekingalpha.com/symbol/TMF' title='Direxion Daily 30-Year Treasury Bull 3x Shares ETF'>TMF</a>, <a href='https://seekingalpha.com/symbol/TTT' title='ProShares UltraPro Short 20+ Year Treasury ETF'>TTT</a>, <a href='https://seekingalpha.com/symbol/ZROZ' title='PIMCO 25+ Year Zero Coupon U.S. Treasury Index ETF'>ZROZ</a>, <a href='https://seekingalpha.com/symbol/VGLT' title='Vanguard Long-Term Government Bond Index ETF'>VGLT</a>, <a href='https://seekingalpha.com/symbol/TLH' title='iShares 10-20 Year Treasury Bond ETF'>TLH</a>, <a href='https://seekingalpha.com/symbol/UBT' title='ProShares Ultra 20+ Year Treasury ETF'>UBT</a>, <a href='https://seekingalpha.com/symbol/TLO' title='SPDR Barclays Long Term Treasury ETF'>TLO</a>, <a href='https://seekingalpha.com/symbol/DLBS' title='iPath U.S. Treasury Long Bond Bear ETN'>DLBS</a>, <a href='https://seekingalpha.com/symbol/VUSTX' title='Vanguard Long Term Treasury Fund Inv'>VUSTX</a>, <a href='https://seekingalpha.com/symbol/TYBS' title='Direxion Daily 20+ Year Treasury Bear 1x Shares ETF'>TYBS</a>, <a href='https://seekingalpha.com/symbol/DLBL' title='iPath U.S. Treasury Long Bond Bull ETN'>DLBL</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3292321\" data-linked=\"10-year Treasury yield slumps to new 2017 low\" data-tweet=\"$TLT $TBT $TMV - 10-year Treasury yield slumps to new 2017 low https://seekingalpha.com/news/3292321-10-year-treasury-yield-slumps-to-new-2017-low?source=tweet\" data-url=\"https://seekingalpha.com/news/3292321-10-year-treasury-yield-slumps-to-new-2017-low\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292315\" data-ts=\"1504008771\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HMY\" target=\"_blank\">HMY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292315-gold-11-month-high-north-korea-missile-sparks-safe-haven-flight\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gold at 11-month high as North Korea missile sparks safe-haven flight</a></h4><ul>     <li>Gold prices continue to rise as tensions stemming from North Korea's latest missile launch sparked <a href=\"https://seekingalpha.com/news/3292269-flight-safety-amid-korea-tensions\" target=\"_blank\">demand for safe-haven assets</a>, <font color='green'>+0.9%</font> to $1,326.50/oz. after earlier climbing as high as $1,329.70.</li>     <li>&ldquo;There [are] increasing expectations for Pres. Trump to counter-react to the North Korean aggression, which <a href=\"http://www.marketwatch.com/story/gold-hits-11-month-high-as-another-north-korea-missile-sparks-haven-flight-2017-08-29\" target=\"_blank\">may further propel the price upwards</a>,&rdquo; says Sun Global Investments CEO Mihir Kapadia.</li>     <li>Even before the North Korea news, Comex gold had <a href=\"http://www.marketwatch.com/story/gold-pushes-above-1300-as-dollar-wavers-in-harveys-wake-2017-08-28\" target=\"_blank\">closed above $1,300 for the first time since last September.</a></li>     <li>\"Since [gold] broke the $1,300 resistance, I think <a href=\"https://www.cnbc.com/2017/08/28/gold-climbs-to-9-12-month-high-on-rising-north-korea-tensions.html\" target=\"_blank\">the market really changed</a>,\" says Yuichi Ikemizu, Tokyo branch manager at ICBC Standard Bank. \"I don't think gold will be going back to $1,200 any more... there's more bullish factors in this market.\"</li>     <li>The route to $1,375 - roughly where gold peaked in August 2016 - looks &ldquo;<a href=\"https://thetradingstrategist.wordpress.com/2017/08/29/gold-aug-29-2/\" target=\"_blank\">wide open</a>,\" according to trader Petros Steriotis.</li>     <li>DailyFx&rsquo;s John Kicklighter calls the spike a \"<a href=\"https://www.dailyfx.com/forex/video/daily_news_report/2017/08/29/Trading-Video-EURUSD-Inches-Towards-120-Yen-Crosses-and-Gold-Shaken-by-North-Korea-Launch.html\" target=\"_blank\">very impressive development</a> - extending this meaningful technical break and showing that there is perhaps a greater degree of conviction here.\"</li>     <li>Some premarket gainers: <a href='https://seekingalpha.com/symbol/HMY' title='Harmony Gold Mining Company Limited'>HMY</a> <font color='green'>+5.9%</font>, <a href='https://seekingalpha.com/symbol/AU' title='AngloGold Ashanti Limited'>AU</a> <font color='green'>+4.1%</font>, <a href='https://seekingalpha.com/symbol/IAG' title='IAMGOLD Corporation'>IAG</a> <font color='green'>+3.5%</font>, <a href='https://seekingalpha.com/symbol/KGC' title='Kinross Gold Corporation'>KGC</a> <font color='green'>+3.4%</font>, <a href='https://seekingalpha.com/symbol/AUY' title='Yamana Gold Inc.'>AUY</a> <font color='green'>+3.1%</font>, <a href='https://seekingalpha.com/symbol/GFI' title='Gold Fields Limited'>GFI</a> <font color='green'>+3%</font>, <a href='https://seekingalpha.com/symbol/EXK' title='Endeavour Silver Corp.'>EXK</a> <font color='green'>+2.4%</font>, <a href='https://seekingalpha.com/symbol/GG' title='Goldcorp Inc.'>GG</a> <font color='green'>+2.2%</font>, <a href='https://seekingalpha.com/symbol/NG' title='NovaGold Resources, Inc'>NG</a> <font color='green'>+2.1%</font>, <a href='https://seekingalpha.com/symbol/AG' title='First Majestic Silver Corp.'>AG</a> <font color='green'>+2%</font>, <a href='https://seekingalpha.com/symbol/GDX' title='VanEck Vectors Gold Miners ETF'>GDX</a> <font color='green'>+1.9%</font>, ABX <font color='green'>+1.8%</font>, <a href='https://seekingalpha.com/symbol/GOLD' title='Barrick Gold Corporation'>GOLD</a> <font color='green'>+1.7%</font>, <a href='https://seekingalpha.com/symbol/NEM' title='Newmont Mining Corporation &#40;Holding Company&#41;'>NEM</a> <font color='green'>+1.7%</font>, <a href='https://seekingalpha.com/symbol/GLD' title='SPDR Gold Trust ETF'>GLD</a> <font color='green'>+0.7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292315\" data-linked=\"Gold at 11-month high as North Korea missile sparks safe-haven flight\" data-tweet=\"$HMY $HMY $AU - Gold at 11-month high as North Korea missile sparks safe-haven flight https://seekingalpha.com/news/3292315-gold-11-month-high-north-korea-missile-sparks-safe-haven-flight?source=tweet\" data-url=\"https://seekingalpha.com/news/3292315-gold-11-month-high-north-korea-missile-sparks-safe-haven-flight\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292314\" data-ts=\"1504008741\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMGN\" target=\"_blank\">IMGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292314-immunogen-inks-adc-development-deal-jazz-pharma-valued-least-175m-shares-ahead-11-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ImmunoGen inks ADC development deal with Jazz Pharma valued at least $175M; shares ahead 11% premarket</a></h4><ul><li>ImmunoGen (NASDAQ:<a href='https://seekingalpha.com/symbol/IMGN' title='ImmunoGen, Inc.'>IMGN</a>) is up&nbsp;<font color='green'>11%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16925590-jazz-pharmaceuticals-immunogen-inc-announce-strategic-collaboration-option-agreement-develop\" target=\"_blank\">announcement </a>of a collaboration and option agreement with Jazz Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/JAZZ' title='Jazz Pharmaceuticals, Inc.'>JAZZ</a>) for two early-stage hematology-related antibody-drug conjugate &#40;ADC&#41; programs and a third undesignated ADC program.</li><li>The two candidates are Phase 1-stage IMGN779, a CD33-targeted ADC for the potential treatment of acute myeloid leukemia and Phase 1-stage IMGN632, a CD123-targeted ADC for the potential treatment of a range of blood cancers.</li><li>Under the terms of the agreement, ImmunoGen will responsible for the development of the three ADCs prior to any opt-in by Jazz. If Jazz elects to take over a program, it will be responsible for further development, regulatory submissions and commercialization.</li><li>ImmunoGen will receive an upfront payment of $75M and up to $100M over seven years to support development. Jazz may opt-in at any time prior to the start of a pivotal study or any time prior to a BLA filing by paying an option exercise fee of mid-double-digit millions or low-triple-digit millions, respectively.</li><li>For each program Jazz elects to take, ImmunoGen will receive milestone payments and tiered royalties on net sales from mid-to-high-single-digit to low-20%. The companies will share development and regulatory submission costs in the U.S. and EU. ImmunoGen has the right to co-commercialize one product in the U.S. (two under certain conditions) and can elect to share profits in the U.S. in lieu of U.S. milestone payments and applicable royalties.</li><li>Jazz will host a conference call today at 4:30 pm ET to discuss the deal.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292314\" data-linked=\"ImmunoGen inks ADC development deal with Jazz Pharma valued at least $175M; shares ahead 11% premarket\" data-tweet=\"$IMGN $IMGN $JAZZ - ImmunoGen inks ADC development deal with Jazz Pharma valued at least $175M; shares ahead 11% premarket https://seekingalpha.com/news/3292314-immunogen-inks-adc-development-deal-jazz-pharma-valued-least-175m-shares-ahead-11-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3292314-immunogen-inks-adc-development-deal-jazz-pharma-valued-least-175m-shares-ahead-11-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292309\" data-ts=\"1504008250\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HAIN\" target=\"_blank\">HAIN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292309-hain-celestial-rallies-after-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hain Celestial rallies after earnings</a></h4><ul> <li>Hain Celestial (NASDAQ:<a href='https://seekingalpha.com/symbol/HAIN' title='The Hain Celestial Group, Inc.'>HAIN</a>) flies after <a href=\"https://seekingalpha.com/pr/16925690-hain-celestial-announces-fourth-quarter-fiscal-year-financial-2017-results\" target=\"_blank\">FQ4</a> results arrive ahead of expectations.</li> <li>Sales in the U.S. rose 1% to $391M during the quarter.</li> <li>Operating income margin came in at 9.7% of sales.</li> <li>\"We are well-positioned among some of the fastest growing trends, categories and channels in consumer products today and are fortunate to have the financial flexibility to support our future business growth and capital allocation priorities,\" says CEO Irwin Simon.</li> <li>Looking ahead, Hain sees full year revenue of $2.967B to $3.036B vs. $2.97B consensus and EPS of $1.63 to $1.80 vs. $1.65 consensus.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3292305-hain-celestial-beats-0_03-beats-revenue\" target=\"_blank\">Hain Celestial beats by $0.03, beats on revenue</a> (Aug. 29)</li> <li>HAIN <font color='green'>+10.79%</font> premarket to $44.99.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292309\" data-linked=\"Hain Celestial rallies after earnings\" data-tweet=\"$HAIN - Hain Celestial rallies after earnings https://seekingalpha.com/news/3292309-hain-celestial-rallies-after-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3292309-hain-celestial-rallies-after-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292304\" data-ts=\"1504007120\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACOR\" target=\"_blank\">ACOR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292304-fda-rejects-acordas-marketing-application-for-parkinsons-candidate-inbrija-shares-down-24\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA rejects Acorda&#39;s marketing application for Parkinson&#39;s candidate Inbrija; shares down 24% premarket</a></h4><ul><li>Acorda Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ACOR' title='Acorda Therapeutics, Inc.'>ACOR</a>) slumps&nbsp;<font color='red'>24%</font>&nbsp;premarket on average volume in response to its <a href=\"https://seekingalpha.com/pr/16925648-acorda-receives-refusal-file-letter-fda-inbrija-cvtminus-301-levodopa-inhalation-powder-new\" target=\"_blank\">announcement </a>that it received a Refusal to File &#40;RTF&#41;&nbsp;letter from the FDA regarding its New Drug Application &#40;NDA&#41; seeking approval for INBRIJA (formerly CVT-301) for the treatment of OFF periods in patients with Parkinson's disease taking a carbidopa/levodopa regimen.</li><li>An RTF means that the company's NDA was not complete enough for review. The specific issues were the date that the manufacturing site would be ready for inspection and a question regarding the submission of the drug master production record. The agency also requested additional information at resubmission that is outside of the RTF.</li><li>The company says it will immediately seek guidance from the FDA, including a Type A meeting, to clarify what is needed for resubmission, adding that the regulator has not requested additional efficacy or safety data.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3271702-acorda-therapeutics-plus-8_5-percent-positive-results-parkinsons-disease-drug\" target=\"_blank\">Acorda Therapeutics +8.5% on positive results in Parkinson's disease drug</a> (June 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3292304\" data-linked=\"FDA rejects Acorda&#39;s marketing application for Parkinson&#39;s candidate Inbrija; shares down 24% premarket\" data-tweet=\"$ACOR - FDA rejects Acorda&#39;s marketing application for Parkinson&#39;s candidate Inbrija; shares down 24% premarket https://seekingalpha.com/news/3292304-fda-rejects-acordas-marketing-application-for-parkinsons-candidate-inbrija-shares-down-24?source=tweet\" data-url=\"https://seekingalpha.com/news/3292304-fda-rejects-acordas-marketing-application-for-parkinsons-candidate-inbrija-shares-down-24\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292300\" data-ts=\"1504006580\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SFUN\" target=\"_blank\">SFUN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292300-fang-holdings-down-6_35-after-q2-shows-continuing-strategy-change\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fang Holdings down 6.35% after Q2 shows continuing strategy change</a></h4><ul><li>        Fang Holdings (NYSE:<a href='https://seekingalpha.com/symbol/SFUN' title='Fang Holdings Ltd. ADS'>SFUN</a>) shares&nbsp;<font color='red'>down 6.35%</font>&nbsp;premarket after reporting Q2 results with estimate misses and revenue that slipped nearly 62% on the year. The declines of the quarter were largely due to the company&rsquo;s ongoing strategy of returning to an open-platform strategy allowing for better mutual relationships with developers, buyers, property owners and other potential partners.</li><li>               Segment revenue: E-commerce services $22.9M (-87.9%); Marketing services, $35 (-31.9%); Listing services, $42.3M (+57.4%); Internet financial services, $2.7M (-75.7%); Other value-added services, $7.1M (-11.2%).&nbsp;</li><li>               Fang reported $23.1M in cash from operating activities and had $547.1M in cash and equivalents at the end of the quarter.&nbsp;</li><li>               Outlook was kept vague with Fang saying it plans to return to profitability in 2H after completing the last stage of the strategy change.&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/16925585-fang-announces-second-quarter-2017-results\" target=\"_blank\">Press release</a>&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3292280-fang-holdings-misses-0_03-misses-revenue\" target=\"_blank\">Fang Holdings misses by $0.03, misses on revenue</a> (Aug. 29)</li></ul><div class=\"tiny-share-widget\" data-id=\"3292300\" data-linked=\"Fang Holdings down 6.35% after Q2 shows continuing strategy change\" data-tweet=\"$SFUN - Fang Holdings down 6.35% after Q2 shows continuing strategy change https://seekingalpha.com/news/3292300-fang-holdings-down-6_35-after-q2-shows-continuing-strategy-change?source=tweet\" data-url=\"https://seekingalpha.com/news/3292300-fang-holdings-down-6_35-after-q2-shows-continuing-strategy-change\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292297\" data-ts=\"1504005542\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BBY\" target=\"_blank\">BBY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292297-best-buy-rallies-after-lifting-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Best Buy rallies after lifting guidance</a></h4><ul> <li>Best Buy (NYSE:<a href='https://seekingalpha.com/symbol/BBY' title='Best Buy Co.'>BBY</a>) reports comparable sales rose 5.4% in the U.S. to smash the estimates of analysts.</li> <li>U.S. appliance comparable sales were up 5.8% and comparable sales in the U.S. computing/mobile phone category were 6.7% higher.</li> <li>The retailer says U.S. revenue was $8.27B, while international revenue came in at $668M. Domestic comparable online sales roared 31% higher. As a percentage of revenue, domestic online sales rose to 13.2% from 10.6%.</li> <li>\"The increased topline expectations are being driven by the anticipation of continued positive industry and consumer momentum, coupled with the impact of product launches. From a profitability perspective, while our original full year guidance anticipated an increased level of investments for FY18,\" says Best Buy CFO Corie Barry.</li> <li>The company expects Q3 revenue of $9.3B to $9.4B vs. $9.0B consensus and EPS of $0.75 to $0.80 vs. $0.65 consensus.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3292289-best-buy-beats-0_06-beats-revenue\" target=\"_blank\">Best Buy beats by $0.06, beats on revenue</a> (Aug. 29)</li> <li>BBY <font color='green'>+3.87%</font> premarket to $64.90.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292297\" data-linked=\"Best Buy rallies after lifting guidance\" data-tweet=\"$BBY - Best Buy rallies after lifting guidance https://seekingalpha.com/news/3292297-best-buy-rallies-after-lifting-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3292297-best-buy-rallies-after-lifting-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292289\" data-ts=\"1504004545\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BBY\" target=\"_blank\">BBY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292289-best-buy-beats-0_06-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Best Buy beats by $0.06, beats on revenue</a></h4><ul><li>Best Buy (NYSE:<a href='https://seekingalpha.com/symbol/BBY' title='Best Buy Co.'>BBY</a>): Q2 EPS of $0.69 <font color='green'>beats by $0.06</font>.</li><li>Revenue of $8.94B (+4.8% Y/Y) <font color='green'>beats by $280M</font>.</li><li>Shares <font color='green'>+5.81%</font> PM.</li><li><a href='https://seekingalpha.com/pr/16925654-best-buy-reports-better-expected-second-quarter-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3292289\" data-linked=\"Best Buy beats by $0.06, beats on revenue\" data-tweet=\"$BBY - Best Buy beats by $0.06, beats on revenue https://seekingalpha.com/news/3292289-best-buy-beats-0_06-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3292289-best-buy-beats-0_06-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:02 AM </div></div></li>","count":45,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}